Recently added
This page was added on 04 June 2018.
Updates made
This page was updated on [date-counter-updated-date]. View history of updates
Sponsor
Merck Sharp & Dohme (Australia)
Administration route
Oral
Vaccine group
Rotavirus vaccines
Description:
Registered for use in infants, with an upper age limit for dose 3 of 32 weeks.
Live attenuated pentavalent human–bovine reassortant rotavirus vaccine
Each 2.0 mL monodose pre-filled dosing tube contains:
- a minimum dose level of at least 2.0 x 106 infectious units of each of the rotavirus reassortants G1, G2, G3, G4 and P1A[8] derived from rotaviruses infecting human and bovine species
- sodium citrate
- sodium phosphate monobasic monohydrate
- sodium hydroxide
- polysorbate 80
- cell culture medium
For Product Information and Consumer Medicine Information about RotaTeq visit the Therapeutic Goods Administration website.
Additional vaccine information
For detailed advice on vaccine dosage, administration, contraindications and precautions, and variations from product information, please visit the relevant disease chapter/s.
Related diseases
Page history
Last updated
Last reviewed